ReviewMolecular biology reports2026
Targeting pyroptosis in intestinal and systemic inflammatory diseases: mechanisms and therapeutic opportunities.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pyroptosis is a lytic form of programmed cell death driven by gasdermin cleavage and subsequent plasma membrane pore formation, which triggers cell swelling, lysis, and the release of inflammatory cytokines that amplify tissue injury. Once viewed as an innate antimicrobial defense mechanism, pyroptosis is now recognized as a central pathogenic pathway in both acute and chronic inflammatory diseases, including inflammatory bowel disease (IBD). Its execution proceeds through a cascade of druggable events-inflammasome assembly, caspase activation, and gasdermin pore formation-and it operates within an interconnected cell death network, engaging apoptosis, necroptosis, and ferroptosis under the emerging PANoptosis framework. In the intestine, this network displays striking cell type- and context-dependent duality: gasdermin-mediated death can disrupt the epithelial barrier and exacerbate mucosal inflammation, yet the same effectors support barrier integrity, epithelial repair, and controlled cytokine release. This duality may explain why pyroptosis inhibition, although robustly protective in preclinical colitis models, has so far shown limited clinical efficacy. In this review, we summarize the molecular mechanisms of pyroptotic signaling, its crosstalk with other death pathways, and its roles in intestinal and systemic inflammatory diseases. We then critically evaluate the therapeutic landscape, covering NLRP3 inflammasome inhibitors, regulators of gasdermin post-translational modifications, natural compounds, and nanotechnology-based delivery systems, with emphasis on multi-indication clinical progress and the lessons from recent trial failures. Finally, we highlight priorities for translation-human disease models, tissue-restricted delivery, and biomarker-guided patient stratification-that may convert mechanistic insight into clinical benefit for patients with IBD and related inflammatory disorders.
Indexed as
Identifiers
42900259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.